Prior attempts to characterize potential blood biomarkers have focused on NF2-related schwannomatosis rather than the more common sporadic VS, which comprises >90% of cases (2, 3) and had limited sample sizes (<30 patients) (14–16). Here, NF2 is linked to schwannomatosis.